Scientia Advisors in the News

---

Publications

---

Press Releases

---

Events

---

Luminary Insights

---

Media Contact

---

Webinars

Biosimilars' Impact on the Bioproduction Paradigm: How to Navigate the Dramatic Changes

Topic:

While the historical growth of bioproduction has closely tracked the approval of biologically derived pharmaceuticals, recent regulatory modifications have driven dramatic changes in the market and have brought new players into the space. These new players include contract manufacturers, branded pharmaceutical developers and generic pharmaceutical companies. The potential growth of the biosimilar market in Europe and the biosimilar regulatory pathway, included in the recently passed U.S. healthcare reform, promise to dramatically change the landscape for bioproduction.

You will learn about Scientia Advisors' perspectives on:

• Biologics and bioproduction market sizing and potential for biosimilars
• Bioproduction market trends and dynamics
• Potential growth paths for bioproduction

Session speaker:

• Amit Argawal, Partner at Scientia Advisors

Who should attend

Executives with responsibility for product and lifecycle management at:

• Contract manufacturers
• Branded pharmaceutical developers
• Generic pharmaceutical companies